$7.9 B

ALNY Mkt cap, 04-Dec-2018

$2.1 M

Alnylam Pharmaceuticals Revenue Q3, 2018
Alnylam Pharmaceuticals Gross profit (Q3, 2018)1.9 M
Alnylam Pharmaceuticals Gross profit margin (Q3, 2018), %93.4%
Alnylam Pharmaceuticals Net income (Q3, 2018)-245.3 M
Alnylam Pharmaceuticals EBIT (Q3, 2018)-254.6 M
Alnylam Pharmaceuticals Cash, 30-Sep-2018316.6 M
Alnylam Pharmaceuticals EV7.6 B

Alnylam Pharmaceuticals Income Statement

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

R&D expense

113.0m276.5m382.4m390.6m

General and administrative expense

27.2m60.6m89.4m199.4m

Operating expense total

140.1m337.1m471.7m590.0m

EBIT

(92.9m)(405.0m)(296.0m)(424.6m)(500.1m)

Interest income

1.1m5.9m8.3m12.2m

Pre tax profit

(91.9m)(290.1m)(410.1m)

Income tax expense

2.7m

Net Income

(89.2m)(360.4m)(290.1m)(410.1m)(490.9m)

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Revenue

2.1m

Cost of goods sold

137.0k

Gross profit

1.9m

Gross profit Margin, %

93%

R&D expense

34.5m43.8m44.7m46.3m58.0m67.0m68.6m96.3m83.2m97.9m87.0m90.6m95.3m96.9m137.6m139.9m

General and administrative expense

6.8m8.9m11.5m9.9m12.7m14.6m16.0m21.1m18.0m22.4m38.5m45.8m47.6m72.4m84.7m116.5m

Operating expense total

41.2m277.3m52.3m56.2m70.8m81.6m84.7m117.4m101.2m120.3m125.5m136.4m142.9m169.3m222.3m256.6m

EBIT

(32.2m)(269.1m)(45.0m)(45.2m)(52.2m)(72.9m)(78.3m)(110.0m)(92.4m)(106.7m)(106.5m)(120.5m)(125.8m)(147.4m)(192.4m)(254.6m)

EBIT margin, %

(12303%)

Interest income

290.0k333.0k693.0k753.0k1.0m1.6m1.6m1.8m2.1m2.2m2.1m2.6m3.3m5.8m6.1m6.8m

Pre tax profit

(32.0m)(268.8m)(44.4m)(43.9m)(51.2m)(71.4m)(76.8m)(103.0m)(90.1m)(141.3m)(163.5m)(244.8m)

Income tax expense

2.3m315.0k(67.0k)(431.0k)(431.0k)62.0k(79.0k)(445.0k)

Net Income

(29.7m)(250.9m)(44.1m)(44.0m)(50.8m)(71.8m)(76.8m)(103.0m)(90.1m)(104.1m)(107.3m)(118.4m)(122.9m)(141.2m)(163.6m)(245.3m)

Alnylam Pharmaceuticals Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

53.2m75.2m180.9m193.6m645.4m

Accounts Receivable

17.9m

Inventories

3.9m9.7m16.6m21.7m

Current Assets

254.0m746.4m1.1b671.9m1.8b

PP&E

16.4m21.7m27.8m114.6m181.9m

Total Assets

420.5m1.1b1.4b1.3b2.0b

Accounts Payable

5.9m15.1m16.8m54.5m28.4m

Short-term debt

Current Liabilities

53.9m95.3m62.1m131.7m144.3m

Long-term debt

150.0m30.0m

Total Debt

150.0m30.0m

Total Liabilities

150.2m121.8m342.6m228.3m

Additional Paid-in Capital

846.2m1.8b2.5b2.6b3.9b

Retained Earnings

(596.2m)(956.6m)(1.2b)(1.7b)(2.1b)

Total Equity

270.3m936.3m1.3b920.2m1.8b

Debt to Equity Ratio

0.2 x0 x

Debt to Assets Ratio

0.1 x0 x

Financial Leverage

1.6 x1.2 x1.1 x1.4 x1.1 x

Alnylam Pharmaceuticals Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(89.2m)(360.4m)(290.1m)(410.1m)(490.9m)

Depreciation and Amortization

10.2m11.9m19.1m15.1m13.4m

Accounts Receivable

Inventories

Accounts Payable

1.8m8.8m1.7m10.1m(4.9m)

Cash From Operating Activities

(68.7m)(165.6m)(189.1m)(307.7m)(382.8m)

Purchases of PP&E

(4.0m)(9.0m)(12.9m)(64.6m)(104.2m)

Cash From Investing Activities

(130.5m)(548.8m)(321.3m)142.6m(290.4m)

Long-term Borrowings

(120.0m)

Cash From Financing Activities

200.9m736.5m616.2m177.8m1.1b

Interest Paid

1.1m2.4m

Income Taxes Paid

114.0k

Alnylam Pharmaceuticals Ratios

USDY, 2018

EV/EBIT

-30 x

EV/CFO

-18.5 x

Financial Leverage

1.1 x
Report incorrect company information

Alnylam Pharmaceuticals Employee Rating

4.276 votes
Culture & Values
3.7
Work/Life Balance
3.5
Senior Management
3.7
Salary & Benefits
4.2
Career Opportunities
3.7
Source